+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 50Years
FEMALE
ID04046900

Study of Vaginal Microbiota Transplant With Antibiotics to Restore Healthy Vaginal Bacteria in Women With Recurrent Bacterial Vaginosis

Led by Douglas Kwon · Updated on 2026-09-11

62

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying vaginal microbiota transplant VMT as a potential way to restore a healthy vaginal bacterial community dominated by Lactobacillus in women with recurrent bacterial vaginosis BV. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety of VMT and compare its effects combined with antibiotics to antibiotics alone in establishing a Lactobacillus-dominant vaginal environment. The trial focuses on women with a history of recurrent BV and hypothesizes that VMT may reduce inflammation and increase Lactobacillus prevalence compared to antibiotic treatment by itself. Participants are randomly assigned to receive either two doses of vaginal fluid from healthy donors VMT or two doses of sterile saline as a placebo. All participants receive a 7-day course of oral Metronidazole 500mg twice daily before transplant administration. The donor vaginal fluid is collected safely using a disposable menstrual cup, and donors undergo extensive infection testing. The study includes two transplant administration visits during week 2 and a series of follow-up visits at weeks 3, 5, 7, 11, 15, and 27 to monitor outcomes and safety. Participants will have multiple study visits including a phone pre-screen, a screening visit with physical and pelvic exams, blood and vaginal sample collections, and education on sample collection procedures. During follow-up visits, participants provide vaginal swabs, soft cup collections, and complete symptom and sexual behavior assessments. Blood samples are taken at selected visits to monitor safety. The primary outcome is the presence of a Lactobacillus crispatus-dominant microbiome five weeks after intervention, with additional measures tracking microbiome presence and adverse events through six months after treatment.

CONDITIONS

Brief Title

Vaginal Microbiota Transplant

Research Team

D

Doug Kwon, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here